Protein Supplementation In Dialysis Patients
Launched by NATIONAL UNIVERSITY OF MALAYSIA · Dec 3, 2017
Trial Information
Current as of May 07, 2025
Completed
Keywords
ClinConnect Summary
This study is a randomised, open labeled controlled trial where a total of 74 PD patients (37 supplemented; 37 control) were recruited from government and private settings. Subjects were randomised to either the intervention or control group. The intervention group received hydrolysed whey protein supplement and diet counselling for 6 months while the control group received only diet counselling for 6 months.
Patients who consented were first subjected to a screening for identification of eligible subjects. The screening involved basic anthropometry measures (height, weight, BMI), routine ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged \> 18 years old and ≤70 years old
- • Undergone dialysis at least for 6 months.
- • Categorised as malnourished based on BMI \<24 kg/m² and serum albumin ≤40 g/L criteria
- • No incidence of hospitalisation for past 3 months, free of infection/sepsis and have not undergone surgery for past 6 months.
- Exclusion Criteria:
- • Patients with high inflammatory diseases, malignancy, cancer
- • Vegetarian patients
About National University Of Malaysia
The National University of Malaysia (Universiti Kebangsaan Malaysia, UKM) is a prestigious institution dedicated to advancing medical research and clinical trials that contribute significantly to the fields of healthcare and biomedical sciences. As a leading academic and research university, UKM is committed to fostering innovation and excellence in clinical research, promoting collaboration among multidisciplinary teams, and enhancing the quality of patient care. The university's robust infrastructure and experienced research faculty facilitate rigorous clinical trials aimed at addressing critical health challenges, thereby improving health outcomes both locally and globally. Through its dedication to ethical research practices and adherence to regulatory standards, UKM strives to enhance the understanding of diseases and develop effective interventions that benefit society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Tilakavati Karupaiah
Principal Investigator
Senior Lecturer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials